Optometric Management Magazine

The Vision Council Foundation has launched a new back-to-school campaign aimed at promoting comprehensive eye exams and healthy vision habits for children among eyecare providers, schools, and families, according to a press release. The “See What Matters – Empowering Education” campaign focuses on childhood myopia, digital eye strain, and dry eye associated with screen use, all of which can affect students.

Bausch + Lomb announced in a press release that its first-in-class dual-action eye drop, designed to address both ocular surface inflammation and tear evaporation, will advance to a phase 3 trial. The eye drop combines 5% lifitegrast (the active ingredient in Xiidra) and perfluorohexyloctane (PFHO; the active ingredient in Miebo) into a single twice-daily treatment.

Bausch + Lomb announced in a press release that it has developed BL1332, a first-in-class topical TRPV1 antagonist designed to target a key receptor involved in ocular pain signaling. The investigational therapy is being evaluated as a potential treatment for multiple forms of ocular surface pain, including postsurgical, acute, and chronic conditions.

Avulux announced the US Food and Drug Administration (FDA) has granted the company De Novo marketing authorization. The authorization establishes a defined FDA-recognized classification for Avulux, which is designed to help manage light sensitivity associated with migraine, the company said in a press release. Avulux migraine and light sensitivity lenses.

The US Food and Drug Administration (FDA) announced a Class II recall for 39,060 15mL-bottles of Clear Eyes Maximum Itchy Eye Relief distributed nationwide. Prestige Brands Holdings voluntarily initiated the ongoing recall due to lack of assurance of sterility and potential contamination. The recall was initiated on July 29 and classified as Class II by the FDA on August 14.

Sight Sciences, Inc.

The World Council of Optometry (WCO) and Alcon dry eye initiative is partnering with the International Association of Contact Lens Educators (IACLE) to help university instructors easily access the program’s range of digital learning tools including the WCO Alcon Dry Eye Wheel and the Dry Eye Management Map. IACLE members can gain direct access from the IACLE Teaching Online Platform (IACLETOP) learning management system.

EyePoint reported top-line results from the phase 3 LUGANO trial of Duravyu (vorolanib intravitreal insert) 2.7 mg in patients with wet age-related macular degeneration (AMD). The study missed its primary endpoint in the full dataset but met several secondary endpoints. The primary endpoint assessed change from baseline in best-corrected visual acuity compared with on-label 2 mg aflibercept. Duravyu did not achieve noninferiority in the full analysis.

Zeiss Medical Technology announced the 510k clearance from the US Food and Drug Administration (FDA) for Zeiss Clinic 360, an all-in-one cloud and browser-based software solution. According to a company press release, Zeiss Clinic 360 combines diagnostic and medical data into a comprehensive patient view that allows clinicians to evaluate disease progression, support treatment decisions, and improve workflow efficiency.

Exposure to indigo light prevented myopia in a tree shrew model with human-like visual characteristics, according to research led by Cincinnati Children’s and the University of Alabama at Birmingham (UAB). The study, published online August 18 in Cell Reports Medicine, focused on short-wavelength indigo light, which is abundant in sunlight but is poorly represented in standard white LED lighting.